Graft Polymer (UK) - Directorate Change

Solvonis Therapeutics

12/08/2024 10:21

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20240812:nRSL0877Aa&default-theme=true

RNS Number : 0877A  Graft Polymer (UK) PLC  12 August 2024

12 August 2024

 

Graft Polymer (UK) Plc

("Graft Polymer" or the "Company")

 

Director resignation

 

Graft Polymer (UK) Plc (LON: GPL), an innovative biopolymer drug delivery
systems development company, announces the resignation, with immediate effect,
of Yifat Steuer from its board of directors and from the role of Chief
Financial Officer.

Orana Corporate LLP will continue to provide support in relation to the
Company's financial function whilst the Company proceeds to select a new CFO.

Nicholas Nelson, Chairman, commented:

"Yifat departs us with our sincere thanks for all she has done during the
transitionary period since I became Chairman. She has provided us with
invaluable guidance and professionalism.

"New board appointments are planned to steer the Company as it pursues its
mission to innovate in drug delivery solutions. "

 

Enquiries:

Graft Polymer (UK) Plc

Anthony Tennyson, CEO and Executive Director

Email: anthonytennyson@graftpolymer.co.uk

 

Allenby Capital (Broker)

Nick Naylor / Liz Kirchner (Corporate Finance) | Guy McDougall (Sales)

+44 (0) 20 3328 5656

 

 

About Graft Polymer (UK) Plc

Graft Polymer plc ("Graft Polymer") (LON: GPL) is an innovative biopolymer
drug delivery systems development company dedicated to enabling
biopharmaceutical companies to enhance the effectiveness of their
therapeutics. Our proprietary platform, a bioabsorbable self-nanoemulsifying
drug delivery system (SNEDDS), represents a cutting-edge solution in drug
delivery technology. By integrating active pharmaceutical ingredients (APIs)
into our novel, patented delivery systems, we enable clients to improve the
pharmacokinetics, bioavailability, and stability of their therapeutics.

 

For more information, please visit www.graftpolymer.co.uk.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  BOAGCGDIGDBDGSD